JAK Inhibitors for Vitiligo Are No Longer Just Cosmetic

The Lancet published a comment on oral JAK inhibitors for vitiligo, signaling a major shift in how this immune-mediated skin condition is treated. Historically trivialized as cosmetic, new targeted oral treatments like ruxolitinib are getting regulatory approval, forcing a medical reevaluation. This means real relief for the millions of people living with depigmented skin, especially those with darker tones where vitiligo is often highly stigmatizing.